Table 1.
Glucose-lowering drugs eligible for the comparator GLD group.
| Blood GLDs (excluding insulin) by ATC subgroup | Active substance |
|---|---|
| A10BA, biguanidesa | Metformin |
| A10BB, sulfonylureasa | Glibenclamide |
| Tolbutamide | |
| Glibornuride | |
| Gliclazide | |
| Glimepiride | |
| Carbutamide | |
| Chlorpropamide | |
| Tolazamide | |
| Glipizide | |
| Gliquidone | |
| Acetohexamide | |
| Glisoxepide | |
| A10BC, sulfonamides (heterocyclic)a,b | Glymidine |
| A10BD, combinations | Metformin/sulfonylureas |
| Metformin/rosiglitazone | |
| Rosiglitazone/glimepiride | |
| Pioglitazone/metformin | |
| Pioglitazone/glimepiride | |
| Sitagliptin/metformin | |
| Vildagliptin/metformin | |
| Pioglitazone/alogliptin | |
| Metformin/saxagliptin | |
| Metformin/linagliptin | |
| Pioglitazone/sitagliptin | |
| Metformin/alogliptin | |
| Metformin/repaglinide | |
| Metformin/acarbose | |
| Metformin/gemigliptin | |
| A10BF, alpha glucosidase inhibitors | Acarbose |
| Voglibose | |
| Miglitol | |
| A10BG, thiazolidinediones | Pioglitazone |
| Rosiglitazone | |
| A10BH, DPP-4 (dipeptidyl peptidase-4) inhibitors | Sitagliptin |
| Vildagliptin | |
| Saxagliptin | |
| Linagliptin | |
| Alogliptin | |
| Sitagliptin/simvastatin | |
| A10BH, DPP-4 combinations | Alogliptin/metformin |
| Linagliptin/metformin | |
| A10BJ, glucagon-like peptide-1 (GLP-1) analogues | Exenatide |
| Liraglutide | |
| Lixisenatide | |
| Albiglutide | |
| Dulaglutide | |
| Semaglutide | |
| A10BX, other | Repaglinide |
| Nateglinide | |
| Mitiglinide |
ATC Anatomical Therapeutic Chemical (classification system), GLD glucose-lowering drug
aDrugs in this class qualified as comparator GLDs only when prescribed in combination with other GLDs
bSulfonamides (heterocyclic) were classified in the sulfonylurea drug class in these studies given the similar mechanism of action to sulfonylureas
Source: World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2020. Available at: http://www.whocc.no/atc_ddd_index/. Accessed 08 May 2020